Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
复制标题
DOI：
10.1097/jto.0b013e3182307e06
复制
发表时间：
2011-12-01
影响因子：
20.4
通讯作者：
Stiber, Jonathan A.
中科院分区：
文献类型：
--
作者：
Ou, Sai-Hong Ignatius;Azada, Michele;Stiber, Jonathan A.
克唑替尼是一种MET/ALK双重抑制剂，目前正处于治疗间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）的高级临床开发阶段。我们观察了几例发生严重但无症状的窦性心动过缓（HR
Crizotinib, a dual MET/ALK inhibitor, is now in advanced clinical development for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We have observed several patients who developed profound but asymptomatic sinus bradycardia (HR